Clinical Trial

Promoting Immunotherapy Efficacy With Low-Dose Liver RT

Study acronym: PRIME-LRT
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to see if adding Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS). This study is for patients with either melanoma or non-small cell lung cancer (NSCLC), with liver metastases, and receiving immunotherapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-11-03; most recent amendment 2026-02-25.
Status change: Not Yet Recruiting → Recruiting 2025-12-16
Trial Details
NCT Number NCT07225036
Lead Sponsor Jordan Kharofa
Conditions Low-Dose Liver Radiation (LD-LRT), Non Small Cell Lung Cancer, Melanoma, Liver Metastases
Enrollment 21 participants
Start Date 2025-12-15
Primary Completion 2027-06-15 (estimated)
Study Completion 2029-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-02-27